Qiagen NV (QGEN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $10.30B
Last updated: Nov 17, 2026 at 11:06 AM ET
Qiagen NV (QGEN) Earnings: Report Dates and Results
Qiagen NV (QGEN) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, Qiagen NV reported EPS of $0.65, above the $0.63 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
QGEN has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 8.1% above the $0.62 reported for the quarter ended Dec 31, 2025.
QGEN Earnings Call
The latest QGEN earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 40 quarters below that had an estimate, QGEN beat 32, missed 2 and matched 6. Revenue for the quarter ended Sep 30, 2026 was $547.87M, up 2.9% from $532.58M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.65 | $0.63 | $0.61 - $0.65 | +3.17% | Beat | +1.6% | 9 | 1 up, 0 down | Nov 4, 2026 | $547.87M |
| Jun 30, 2026 | $0.62 | $0.60 | $0.59 - $0.61 | +3.33% | Beat | -1.6% | 10 | 1 up, 0 down | Aug 5, 2026 | $535.04M |
| Mar 31, 2026 | $0.54 | $0.54 | $0.54 - $0.54 | 0.00% | In line | -6.9% | 3 | 0 up, 0 down | May 6, 2026 | $492.32M |
| Dec 31, 2025 | $0.62 | $0.62 | $0.59 - $0.64 | 0.00% | In line | -3.1% | 10 | 0 up, 3 down | Feb 4, 2026 | $540.42M |
| Sep 30, 2025 | $0.64 | $0.62 | N/A | +3.23% | Beat | +3.2% | 11 | 0 up, 2 down | Nov 4, 2025 | $532.58M |
| Jun 30, 2025 | $0.63 | $0.63 | N/A | 0.00% | In line | +5.0% | 11 | 10 up, 0 down | Aug 5, 2025 | $533.54M |
| Mar 31, 2025 | $0.58 | $0.54 | $0.48 - $0.60 | +7.41% | Beat | +16.0% | 12 | 2 up, 0 down | May 7, 2025 | $483.46M |
| Dec 31, 2024 | $0.64 | $0.65 | N/A | -1.54% | Miss | +6.7% | 11 | 1 up, 2 down | Feb 5, 2025 | $521.20M |
| Sep 30, 2024 | $0.62 | $0.59 | N/A | +5.08% | Beat | +10.7% | 12 | 1 up, 0 down | Nov 6, 2024 | $501.87M |
| Jun 30, 2024 | $0.60 | $0.56 | N/A | +7.14% | Beat | +5.3% | 14 | 0 up, 0 down | Jul 31, 2024 | $496.35M |
| Mar 31, 2024 | $0.50 | $0.47 | N/A | +6.38% | Beat | -12.3% | 14 | 0 up, 0 down | Apr 29, 2024 | $458.80M |
| Dec 31, 2023 | $0.60 | $0.60 | N/A | 0.00% | In line | +1.7% | 12 | N/A | Feb 6, 2024 | $509.16M |
| Sep 30, 2023 | $0.56 | $0.54 | N/A | +3.70% | Beat | -5.1% | 11 | 0 up, 1 down | Oct 30, 2023 | $475.89M |
| Jun 30, 2023 | $0.57 | $0.56 | N/A | +1.79% | Beat | 0.0% | 11 | 1 up, 0 down | Aug 8, 2023 | $494.86M |
| Mar 31, 2023 | $0.57 | $0.51 | N/A | +11.76% | Beat | -36.0% | 11 | 0 up, 0 down | May 3, 2023 | $485.40M |
| Dec 31, 2022 | $0.59 | $0.52 | N/A | +13.46% | Beat | -28.9% | 11 | 1 up, 0 down | Feb 7, 2023 | $497.98M |
| Sep 30, 2022 | $0.59 | $0.51 | N/A | +15.69% | Beat | -9.2% | 6 | 1 up, 0 down | Nov 7, 2022 | $499.63M |
| Jun 30, 2022 | $0.57 | $0.51 | N/A | +11.76% | Beat | -24.0% | N/A | 0 up, 0 down | Jul 26, 2022 | $515.51M |
| Mar 31, 2022 | $0.89 | $0.80 | N/A | +11.25% | Beat | +20.3% | 5 | 2 up, 0 down | Apr 26, 2022 | $628.39M |
| Dec 31, 2021 | $0.83 | $0.68 | N/A | +22.06% | Beat | +9.2% | 5 | N/A | Feb 8, 2022 | $582.40M |
| Sep 30, 2021 | $0.65 | $0.60 | N/A | +8.33% | Beat | 0.0% | 6 | N/A | Nov 3, 2021 | $534.75M |
| Jun 30, 2021 | $0.75 | $0.74 | N/A | +1.35% | Beat | +23.0% | 13 | N/A | Jul 29, 2021 | $567.31M |
| Mar 31, 2021 | $0.74 | $0.70 | N/A | +5.71% | Beat | +94.7% | 11 | N/A | May 3, 2021 | $567.21M |
| Dec 31, 2020 | $0.76 | $0.71 | N/A | +7.04% | Beat | +40.7% | 14 | N/A | Feb 9, 2021 | $571.23M |
| Sep 30, 2020 | $0.65 | $0.62 | N/A | +4.84% | Beat | +62.5% | 12 | N/A | Oct 27, 2020 | $483.76M |
| Jun 30, 2020 | $0.61 | $0.54 | $0.35 - $0.55 | +12.96% | Beat | +64.9% | 10 | N/A | Aug 4, 2020 | $443.25M |
| Mar 31, 2020 | $0.38 | $0.30 | $0.18 - $0.31 | +26.67% | Beat | +26.7% | 10 | N/A | May 6, 2020 | $372.10M |
| Dec 31, 2019 | $0.54 | $0.49 | N/A | +10.20% | Beat | +20.0% | 14 | N/A | Feb 4, 2020 | $413.47M |
| Sep 30, 2019 | $0.40 | $0.39 | N/A | +2.56% | Beat | +2.6% | 12 | N/A | Oct 30, 2019 | $382.69M |
| Jun 30, 2019 | $0.37 | $0.37 | N/A | 0.00% | In line | 0.0% | 12 | N/A | Jul 24, 2019 | $381.61M |
| Mar 31, 2019 | $0.30 | $0.29 | N/A | +3.45% | Beat | +3.4% | 10 | N/A | May 6, 2019 | $348.65M |
| Dec 31, 2018 | $0.45 | $0.44 | N/A | +2.27% | Beat | -6.2% | 12 | N/A | Feb 4, 2019 | $403.17M |
| Sep 30, 2018 | $0.39 | $0.37 | N/A | +5.41% | Beat | +8.3% | 11 | N/A | Oct 29, 2018 | $377.91M |
| Jun 30, 2018 | $0.37 | $0.36 | N/A | +2.78% | Beat | +12.1% | 11 | N/A | Jul 31, 2018 | $377.20M |
| Mar 31, 2018 | $0.29 | $0.27 | N/A | +7.41% | Beat | +31.8% | 11 | N/A | May 2, 2018 | $343.57M |
| Dec 31, 2017 | $0.48 | $0.46 | N/A | +4.35% | Beat | +9.1% | 11 | N/A | Jan 31, 2018 | $396.86M |
| Sep 30, 2017 | $0.36 | $0.36 | N/A | 0.00% | In line | +5.9% | 11 | N/A | Nov 6, 2017 | $363.98M |
| Jun 30, 2017 | $0.33 | $0.32 | N/A | +3.13% | Beat | +17.9% | 13 | N/A | Jul 27, 2017 | $348.99M |
| Mar 31, 2017 | $0.22 | $0.23 | N/A | -4.35% | Miss | 0.0% | N/A | N/A | May 2, 2017 | $307.71M |
| Dec 31, 2016 | $0.44 | $0.43 | N/A | +2.33% | Beat | +22.2% | N/A | N/A | Feb 1, 2017 | $366.51M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $2.47, up 4.7% from the year before. It was $1.28 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $2.47 | +4.7% |
| Dec 31, 2024 | $2.36 | +2.6% |
| Dec 31, 2023 | $2.30 | -12.9% |
| Dec 31, 2022 | $2.64 | -11.1% |
| Dec 31, 2021 | $2.97 | +23.8% |
| Dec 31, 2020 | $2.40 | +49.1% |
| Dec 31, 2019 | $1.61 | +7.3% |
| Dec 31, 2018 | $1.50 | +7.9% |
| Dec 31, 2017 | $1.39 | +8.6% |
| Dec 31, 2016 | $1.28 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 7,400 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 7,434 | 12 | |
| 2025Q4 | Dec 31, 2025 | 7,748 | 13 | |
| 2025Q3 | Sep 30, 2025 | 7,587 | 12 | |
| 2025Q2 | Jun 30, 2025 | 7,838 | 16 | |
| 2025Q1 | Mar 31, 2025 | 6,691 | 12 | |
| 2024Q4 | Dec 31, 2024 | 9,233 | 13 | |
| 2024Q3 | Sep 30, 2024 | 8,513 | 12 | |
| 2024Q2 | Jun 30, 2024 | 7,918 | 16 |
2026Q2 Earnings Call
Opening remarks
Daniel Wendorff Vice President, Head of Investor Relations Thank you, operator, and welcome to our call for the second quarter of 2026. We appreciate your time and interest in Qiagen. Joining the call today are Thierry Bernard, our Chief Executive Officer; and Roland Sackers, our Chief Financial Officer. Also joining us is Dr. Domenica Martorana from our Investor Relations team. As always, today's call is being webcast live and will be archived in the Investor Relations section of our website at www.qiagen.com, where you can find the press release and presentation accompanying this call. Please also note that this call will include forward-looking statements. Actual results may differ materially from those projected due to a number of factors outlined in our most recent Form 20-F and other filings with the U.S. Securities and Exchange Commission. We will also refer to certain financial measures not prepared in accordance with U.S. generally accepted accounting principles or GAAP that provide additional insights into our performance. Reconciliations to the most directly comparable GAAP figures are in the release and presentation. All references to earnings per share refer to adjusted diluted EPS. With that, let me hand over the call to you, Thierry.
Thierry Bernard Chief Executive Officer Thank you, Daniel. Hello, and good morning, good afternoon or good evening, depending on where you are in the world, and thank you for joining us. Let me start by thanking again our teams across Qiagen for their continued dedication and disciplined execution. Their focus enabled us to deliver results above our outlook while continuing to invest in our portfolio and focus on profitable growth. Let me now walk you through our key messages for today. First, we exceeded our outlook for both sales and adjusted EPS. Net sales were $535 million and unchanged on both a reported basis and at CER. This was ahead of our outlook for an approximately 2% decline CER. Adjusted diluted EPS was $0.62 on both a reported basis and at CER again, above our outlook of at least $0.60 at CER. Those results demonstrate the resilience of our business and provide further confidence in our outlook for the year. Second key message, our growth pillars delivered 5% growth at CER, profitably above market growth. Sample Technologies led the quarter, reflecting continued demand for our sample preparation solutions. QIAcuity delivered another solid quarter, driven by healthy consumables demand. QDI, our bioinformatics business, also performed well, led by our clinical application. QuantiFERON returned to growth as solid demand across many testing groups more than offset the significant decline in U.S. immigration testing demand. This U.S. immigration testing demand decrease is what we highlighted at the end of our Q1 2026.
Frequently Asked Questions About QGEN
When is Qiagen NV's next earnings date?
Qiagen NV's next earnings report is expected for Feb 2, 2027.
Did QGEN beat earnings estimates last quarter?
Yes. Qiagen NV reported EPS of $0.65 for the quarter ended Sep 30, 2026, above the $0.63 estimate, a 3.17% surprise.
What EPS do analysts expect from QGEN next quarter?
The consensus EPS estimate for Qiagen NV for the quarter ending Dec 31, 2026 is $0.67 from 11 analysts, with estimates from $0.63 to $0.70.
How often does QGEN beat earnings estimates?
Qiagen NV beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +1.95%.
QGEN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts